Table 4.

COVID-19 nasal swab Ct values and percent reduction from baseline specimen after CTL infusion

Interventional patientPre-CTL baselineDay +4Day +7Day +10∗ Day +14
Target 1 (E)Target 2 (ORF1a)Target 1 (E)Target 2 (ORF1a)Target 1 (E)Target 2 (ORF1a)Target 1 (E)Target 2 (ORF1a)Target 1 (E)Target 2 (ORF1a)
CtCtCt% RedCt% RedCt% RedCt% RedCt% RedCt% RedCt% RedCt% Red
1 23.18 24.11 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 
2 20.16 20.54 28.18 99.61 28.65 99.64 27.58 99.42 27.77 99.33 20.41 15.91 20.91 22.62 NLP 100 NLP 100 
3 29.39 29.91 32.41 87.67 33.21 89.85 31.3 73.39 32.82 86.70 NLP 100 NLP 100 NLP 100 NLP 100 
4 19.58 19.86 25.36 98.18 25.96 98.54 33.02 99.99 34.98 99.99 33.34 99.99 36.02 99.99 NLP 100 NLP 100 
5 24.5 24.88 20.43 −1579 20.71 −1700 22.63 −265 23.04 −258 ND  ND  31.74 99.34 32.76 99.58 
6 30.64 32.7 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 
7 18.96 19.18 28.35 99.85 28.45 99.84 33.4 99.99 34.1 99.99 NLP 100 NLP 100 NLP 100 NLP 100 
8 20.01 20.11 25.29 97.43 25.29 97.24 29.65 99.87 29.86 99.88 31.67 99.97 32.6 99.98 27.51 99.45 27.73 99.49 
9 23.92 19.3 27.56 91.98 24.13 96.48 34.03 99.91 31.79 99.98 NLP 100 37.02 99.99 NLP 100 NLP 100 
10 15.63 15.74 27.14 99.97 27.21 99.96 27.53 99.97 27.7 99.97 ND ND ND ND NLP 100 NLP 100 
11 20.47 20.48 NLP 100 NLP 100 TNR TNR TNR TNR TNR TNR TNR TNR TNR TNR TNR TNR 
12 22.2 22.17 30.08 99.58 30.2 99.62 36.91 99.99 NLP 100 NLP 100 NLP 100 TNR TNR TNR TNR 
Interventional patientPre-CTL baselineDay +4Day +7Day +10∗ Day +14
Target 1 (E)Target 2 (ORF1a)Target 1 (E)Target 2 (ORF1a)Target 1 (E)Target 2 (ORF1a)Target 1 (E)Target 2 (ORF1a)Target 1 (E)Target 2 (ORF1a)
CtCtCt% RedCt% RedCt% RedCt% RedCt% RedCt% RedCt% RedCt% Red
1 23.18 24.11 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 
2 20.16 20.54 28.18 99.61 28.65 99.64 27.58 99.42 27.77 99.33 20.41 15.91 20.91 22.62 NLP 100 NLP 100 
3 29.39 29.91 32.41 87.67 33.21 89.85 31.3 73.39 32.82 86.70 NLP 100 NLP 100 NLP 100 NLP 100 
4 19.58 19.86 25.36 98.18 25.96 98.54 33.02 99.99 34.98 99.99 33.34 99.99 36.02 99.99 NLP 100 NLP 100 
5 24.5 24.88 20.43 −1579 20.71 −1700 22.63 −265 23.04 −258 ND  ND  31.74 99.34 32.76 99.58 
6 30.64 32.7 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 NLP 100 
7 18.96 19.18 28.35 99.85 28.45 99.84 33.4 99.99 34.1 99.99 NLP 100 NLP 100 NLP 100 NLP 100 
8 20.01 20.11 25.29 97.43 25.29 97.24 29.65 99.87 29.86 99.88 31.67 99.97 32.6 99.98 27.51 99.45 27.73 99.49 
9 23.92 19.3 27.56 91.98 24.13 96.48 34.03 99.91 31.79 99.98 NLP 100 37.02 99.99 NLP 100 NLP 100 
10 15.63 15.74 27.14 99.97 27.21 99.96 27.53 99.97 27.7 99.97 ND ND ND ND NLP 100 NLP 100 
11 20.47 20.48 NLP 100 NLP 100 TNR TNR TNR TNR TNR TNR TNR TNR TNR TNR TNR TNR 
12 22.2 22.17 30.08 99.58 30.2 99.62 36.91 99.99 NLP 100 NLP 100 NLP 100 TNR TNR TNR TNR 

To determine viral load reduction for each patient, the difference in Ct on each follow-up day from day 0 baseline was determined. Next, the percentage of SARS-CoV-2 burden remaining was calculated by converting the exponent difference to a percentage (ie, 2 to the power of the difference between baseline and remaining). If it took 1 more cycle, 50% of the viral burden would be left; if 2 more cycles, 25 %; 3 cycles, 12.5%, etc. Finally, we converted the percentage remaining to a percentage eliminated by subtracting the percentage remaining from 100%. Each patient in this way was compared with their original Ct (ie, their initial burden).

% Red, Percentage of reduction in viral load from baseline sample; ND, not done; NLP, No longer positive; TNR, testing was not repeated because the patient had previously achieved PCR negativity.

∗

The day +10 testing was not mandatory but was obtained in most patients. PCR testing could be stopped once a negative specimen was obtained. Patients 2 and 3 became PCR negative after treatment for bacterial sinus infection. Patient 2 reported resolution of maxillary sinus pressure at the time her PCR data rebounded, potentially because of opening of a reservoir of virus in her maxillary sinus mucous, which was secluded from CTLs. Patients 5, 8, and 9 were under treatment for lymphoma at the time of COVID-19 diagnosis.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal